{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:26:09Z","timestamp":1786980369132,"version":"build-2736575974"},"reference-count":9,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Liver Journal"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Care cascades are useful tools for tracking progress toward public health goals, including the World Health Organization's target of hepatitis C elimination by 2030. This study outlines the hepatitis C care cascade in Newfoundland and Labrador (NL) from 2018 to 2024 and assesses trends in access to testing and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Provincial administrative health data on hepatitis C testing and treatment dispensing were analyzed. We calculated descriptive statistics for the full study period and compared two time intervals, with additional year-by-year analyses to examine trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>From 2018 to 2024, the annual incidence of hepatitis C antibody positivity was 67.3 per 100,000 population. The diagnosis rate was 71%, and 25.6% of diagnosed individuals initiated treatment. Among those testing positive, the mean age was 40 years, 61% were male, and 31.5% were born between 1945 and 1975. Compared with 2018\u20132021, access to confirmatory RNA testing and treatment initiation improved in 2022\u20132024. Yearly trends showed steady increases in testing and treatment uptake, along with shorter time to treatment; by 2023, most individuals began treatment within 1 year of diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>While access to testing and treatment improved over time, NL has not yet met hepatitis C elimination targets. Targeted interventions for higher-risk populations are needed to accelerate progress.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3138\/canlivj-2026-0022","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:52:41Z","timestamp":1784321561000},"page":"444-449","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the hepatitis C care cascade in Newfoundland and Labrador: Progress toward elimination"],"prefix":"10.3138","volume":"9","author":[{"given":"Cindy","family":"Whitten","sequence":"first","affiliation":[{"name":"Newfoundland and Labrador Health Services, St Johns, Newfoundland, Canada"},{"name":"Memorial University of Newfoundland, St Johns, Newfoundland, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Z","family":"Raza","sequence":"additional","affiliation":[{"name":"Newfoundland and Labrador Health Services, St Johns, Newfoundland, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Daley","sequence":"additional","affiliation":[{"name":"Newfoundland and Labrador Health Services, St Johns, Newfoundland, Canada"},{"name":"Memorial University of Newfoundland, St Johns, Newfoundland, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","reference":[{"key":"e_1_3_10_2_2","unstructured":"The Canadian Network on Hepatitis C Blueprint Writing Committee and Working Groups. Blueprint to inform hepatitis C elimination efforts in Canada. 2019 May. https:\/\/www.canhepc.ca\/en\/hcv-elimination-initiatives (Accessed June 24 2026)."},{"key":"e_1_3_10_3_2","unstructured":"World Health Organization. Hepatitis. https:\/\/www.who.int\/health-topics\/hepatitis\/elimination-of-hepatitis-by-2030 (Accessed March 16 2026)."},{"issue":"1","key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12879-024-09241-z","article-title":"Evaluating hepatitis C cascade of care surveillance system in Tuscany, Italy, through a population retrospective data-linkage study, 2015\u20132021","volume":"24","author":"Ceccarelli L","year":"2024","unstructured":"Ceccarelli L, Moretti G, Mazzilli S, . Evaluating hepatitis C cascade of care surveillance system in Tuscany, Italy, through a population retrospective data-linkage study, 2015\u20132021. BMC Infect Dis. 2024;24(1):362. https:\/\/doi.org\/10.1186\/s12879\u2013024\u201309241-z. Medline: 38553731","journal-title":"BMC Infect Dis"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2024-0003"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14227"},{"issue":"6","key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.14745\/ccdr.v51i67a02","article-title":"National hepatitis B and C estimates for 2021: measuring Canada's progress towards eliminating viral hepatitis as a public health concern","volume":"51","author":"P\u00e9rinet S","year":"2025","unstructured":"P\u00e9rinet S, Williams A, Campeau L, . National hepatitis B and C estimates for 2021: measuring Canada's progress towards eliminating viral hepatitis as a public health concern. Can Commun Dis Rep. 2025;51(6\/7):223\u201337. https:\/\/doi.org\/10.14745\/ccdr.v51i67a02. Medline: 40861921","journal-title":"Can Commun Dis Rep"},{"key":"e_1_3_10_8_2","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis. 2016. https:\/\/apps.who.int\/iris\/handle\/10665\/246177 (Accessed June 15, 2026)."},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/v16030389"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj.2018-0011"}],"container-title":["Canadian Liver Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/canlivj-2026-0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:42:03Z","timestamp":1786977723000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/canlivj-2026-0022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.3138\/canlivj-2026-0022"],"URL":"https:\/\/doi.org\/10.3138\/canlivj-2026-0022","relation":{},"ISSN":["2561-4444"],"issn-type":[{"value":"2561-4444","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}